Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2025 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungen
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to The Report
Fundraising

Neuralink

Neuralink Raises $650M in Series E

2016
Founded
400+
Employees
Fremont, CA
Updated June 2, 2025
2 min read

Quick Facts

Neuralink Raises $650M in Series E


Neuralink has successfully raised $650M in a Series E at a $9B valuation led by Sequoia Capital, Lightspeed, Thrive Capital, ARK Investment Management.


Company Overview


Neuralink is a HealthTech company headquartered in Fremont, CA, founded in 2016 with 400+ employees.


Brain-computer interface company developing implantable devices for paralysis and neurological conditions


Fundraising Details


  • Amount Raised: $650M
  • Round Type: Series E
  • Valuation: $9B
  • Date: 2025-06-02
  • Investors: Sequoia Capital, Lightspeed, Thrive Capital, ARK Investment Management

About Neuralink


Brain-computer interface company developing implantable devices for paralysis and neurological conditions The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Fremont, CA
  • Founded: 2016
  • Team Size: 400+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Neuralink's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Neuralink's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $9B valuation marks an important milestone for Neuralink, positioning the company among notable players in the HealthTech industry.


Looking Ahead


With this new capital, Neuralink is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-06-02. For more information about Neuralink, visit their headquarters at Fremont, CA.

Topics

Fundraising(2912)HealthTech(503)Series ENeuralink

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million